Revenue
No reported data
Alto Neuroscience, Inc. (ANRO)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $45.6M | $47.0M | $30.3M |
| Operating expenses | $66.4M | $68.6M | $37.8M |
| Operating income | −$66.4M | −$68.6M | −$37.8M |
| EBITDAderived | — | −$68.1M | −$37.4M |
| Net income | −$63.2M | −$61.4M | −$36.3M |
| Basic EPSper diluted share | -$2.19 | -$2.50 | -$9.73 |
| Diluted EPSper diluted share | -$2.19 | -$2.50 | -$9.73 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 10, 2024Form 4 | Savitz AdamCHIEF MEDICAL OFFICER | BuyCommon Stock · indirect | 2.9K | $13.22 | $38.7K | 39.9K |
| Jul 9, 2024Form 4 | Savitz AdamCHIEF MEDICAL OFFICER | BuyCommon Stock · indirect | 1.4K | $13.15 | $18.3K | 36.9K |
| Jul 9, 2024Form 4 | Savitz AdamCHIEF MEDICAL OFFICER | BuyCommon Stock · indirect | 10.7K | $12.53 | $133.8K | 35.5K |